A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)

NCT02698189 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
9
Enrollment
INDUSTRY
Sponsor class

Stopped This study was terminated due to limited efficacy and not due to safety reasons

Conditions

Interventions

Sponsor

Merck Sharp & Dohme LLC